# Primary Ciliary Dyskinesia (PCD) - Epidemiology Forecast to 2032 

https://marketpublishers.com/r/P8C85B0D026BEN.html
Date: January 2022
Pages: 60
Price: US\$ 3,950.00 (Single User License)
ID: P8C85B0D026BEN

## Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Primary Ciliary Dyskinesia (PCD) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Primary Ciliary Dyskinesia (PCD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019-2032

Primary Ciliary Dyskinesia (PCD) Understanding

The DelveInsight Primary Ciliary Dyskinesia (PCD) epidemiology report gives a thorough understanding of the Primary Ciliary Dyskinesia (PCD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Primary Ciliary Dyskinesia (PCD) in the US, Europe, and Japan. The report covers the detailed information of the Primary Ciliary Dyskinesia (PCD) epidemiology scenario in seven major countries (US,


#### Abstract

EU5, and Japan).

Primary Ciliary Dyskinesia (PCD) Epidemiology Perspective by DelveInsight

The Primary Ciliary Dyskinesia (PCD) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Primary Ciliary Dyskinesia (PCD) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Primary Ciliary Dyskinesia (PCD) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Primary Ciliary Dyskinesia (PCD) Detailed Epidemiology Segmentation

The Primary Ciliary Dyskinesia (PCD) epidemiology covered in the report provides historical as well as forecasted Primary Ciliary Dyskinesia (PCD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The Delvelnsight Primary Ciliary Dyskinesia (PCD) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

## Scope of the Report

The Primary Ciliary Dyskinesia (PCD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

The Primary Ciliary Dyskinesia (PCD) Epidemiology Report and Model provide an overview of the global trends of Primary Ciliary Dyskinesia (PCD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

The report provides insight into the historical and forecasted patient pool of Primary Ciliary Dyskinesia (PCD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

The report helps recognize the growth opportunities in the 7MM for the patient population

The report assesses the disease risk and burden and highlights the unmet needs of Primary Ciliary Dyskinesia (PCD)

The report provides the segmentation of the Primary Ciliary Dyskinesia (PCD) epidemiology

## Report Highlights

# 11-year Forecast of Primary Ciliary Dyskinesia (PCD) epidemiology 

7MM Coverage

Prevalent and Diagnosed Cases of Primary Ciliary Dyskinesia (PCD)

Cases of Primary Ciliary Dyskinesia (PCD) by Mutation Types

Primary Ciliary Dyskinesia (PCD) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Primary Ciliary Dyskinesia (PCD)?

What are the key findings pertaining to the Primary Ciliary Dyskinesia (PCD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?

What would be the total number of patients of Primary Ciliary Dyskinesia (PCD) across the 7MM during the forecast period (2019-2032)?

Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?

At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

What is the disease risk, burden and unmet needs of Primary Ciliary Dyskinesia (PCD)?

What are the currently available treatments of Primary Ciliary Dyskinesia (PCD)?

## Reasons to buy

The Primary Ciliary Dyskinesia (PCD) Epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global Primary Ciliary Dyskinesia (PCD) market

Quantify patient populations in the global Primary Ciliary Dyskinesia (PCD) market to improve product design, pricing, and launch plans

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Primary Ciliary Dyskinesia (PCD) therapeutics in each of the markets covered

Understand the magnitude of Primary Ciliary Dyskinesia (PCD) population by its epidemiology

The Primary Ciliary Dyskinesia (PCD) Epidemiology Model developed by Delvelnsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

## Key Assessments

Patient Segmentation

Disease Risk \& Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

## Contents

## 1. KEY INSIGHTS

## 2. EXECUTIVE SUMMARY OF PRIMARY CILIARY DYSKINESIA (PCD)

## 3. PRIMARY CILIARY DYSKINESIA (PCD): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

## 4. PATIENT JOURNEY

## 5. EPIDEMIOLOGY AND PATIENT POPULATION

### 5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Primary Ciliary Dyskinesia (PCD) Epidemiology Scenario in the 7MM (20192032)
5.4. United States Epidemiology
5.4.1. Primary Ciliary Dyskinesia (PCD) Epidemiology Scenario in the United States (2019-2032)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Primary Ciliary Dyskinesia (PCD) Epidemiology Scenario in Germany (20192032)
5.5.2. France Epidemiology
5.5.2.1. Primary Ciliary Dyskinesia (PCD) Epidemiology Scenario in France (20192032)
5.5.3. Italy Epidemiology
5.5.3.1. Primary Ciliary Dyskinesia (PCD) Epidemiology Scenario in Italy (20192032)
5.5.4. Spain Epidemiology
5.5.4.1. Primary Ciliary Dyskinesia (PCD) Epidemiology Scenario in Spain (2019-
2032)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Primary Ciliary Dyskinesia (PCD) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
5.6.1. Primary Ciliary Dyskinesia (PCD) Epidemiology Scenario in Japan (2019-2032)

## 6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Primary Ciliary Dyskinesia (PCD) Treatment and Management
6.2. Primary Ciliary Dyskinesia (PCD) Treatment Algorithm

## 7. KOL VIEWS

8. UNMET NEEDS

## 9. APPENDIX

9.1. Bibliography
9.2. Report Methodology
10. DELVEINSIGHT CAPABILITIES

## 11. DISCLAIMER

## 12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

## List Of Tables

## LIST OF TABLES

## List of Table:

Table 1: Primary Ciliary Dyskinesia (PCD) Epidemiology in 7MM (2019-2032)
Table 2: Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Primary Ciliary Dyskinesia (PCD) Epidemiology in the United States (2019-2032)
Table 4: Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Primary Ciliary Dyskinesia (PCD) Epidemiology in Germany (2019-2032)
Table 6: Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Primary Ciliary Dyskinesia (PCD) Epidemiology in France (2019-2032)
Table 8: Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Primary Ciliary Dyskinesia (PCD) Epidemiology in Italy (2019-2032)
Table 10: Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Primary Ciliary Dyskinesia (PCD) Epidemiology in Spain (2019-2032)
Table 12: Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Primary Ciliary Dyskinesia (PCD) Epidemiology in the United Kingdom (2019-2032)
Table 14: Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Primary Ciliary Dyskinesia (PCD) Epidemiology in Japan (2019-2032)
Table 16: Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in Japan (2019-2032)

## List Of Figures

## LIST OF FIGURES

## List of Figures

Figure 1 Primary Ciliary Dyskinesia (PCD) Epidemiology in 7MM (2019-2032)
Figure 2 Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Primary Ciliary Dyskinesia (PCD) Epidemiology in the United States (2019-2032)
Figure 4 Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Primary Ciliary Dyskinesia (PCD) Epidemiology in Germany (2019-2032)
Figure 6 Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Primary Ciliary Dyskinesia (PCD) Epidemiology in France (2019-2032)
Figure 8 Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Primary Ciliary Dyskinesia (PCD) Epidemiology in Italy (2019-2032)
Figure 10 Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Primary Ciliary Dyskinesia (PCD) Epidemiology in Spain (2019-2032)
Figure 12 Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Primary Ciliary Dyskinesia (PCD) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Primary Ciliary Dyskinesia (PCD) Epidemiology in Japan (2019-2032)
Figure 16 Primary Ciliary Dyskinesia (PCD) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report

## I would like to order

Product name: Primary Ciliary Dyskinesia (PCD) - Epidemiology Forecast to 2032
Product link: https://marketpublishers.com/r/P8C85B0D026BEN.html
Price: US\$ 3,950.00 (Single User License / Electronic Delivery)
If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P8C85B0D026BEN.html

## To pay by Wire Transfer, please, fill in your contact details in the form

 below:First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:
**All fields are required
Custumer signature $\qquad$

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms \& Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +442079003970

